The Inflation Reduction Act : Implications for Medicare spending and access to biologic therapies for chronic rhinosinusitis with nasal polyposis and asthma
© 2024 ARS-AAOA, LLC..
KEY POINTS: In 2021, Medicare spending on biologics was $926 million in Part B (FFS) and $1.3 billion in Part D (FFS/MA). Between 2017 and 2021, annual Medicare spending on biologics increased by approximately 200%. Between 2023 and 2025, Medicare Part D OOP costs for biologics will decrease by an estimated 50%-60%.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
International forum of allergy & rhinology - (2024) vom: 11. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rathi, Vinay K [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Benralizumab |
|---|
| Anmerkungen: |
Date Revised 11.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1002/alr.23344 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369555325 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369555325 | ||
| 003 | DE-627 | ||
| 005 | 20240311233213.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240311s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/alr.23344 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1323.xml |
| 035 | |a (DE-627)NLM369555325 | ||
| 035 | |a (NLM)38465800 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rathi, Vinay K |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Inflation Reduction Act |b Implications for Medicare spending and access to biologic therapies for chronic rhinosinusitis with nasal polyposis and asthma |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 11.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024 ARS-AAOA, LLC. | ||
| 520 | |a KEY POINTS: In 2021, Medicare spending on biologics was $926 million in Part B (FFS) and $1.3 billion in Part D (FFS/MA). Between 2017 and 2021, annual Medicare spending on biologics increased by approximately 200%. Between 2023 and 2025, Medicare Part D OOP costs for biologics will decrease by an estimated 50%-60% | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CMS | |
| 650 | 4 | |a CRS | |
| 650 | 4 | |a CRSwNP | |
| 650 | 4 | |a Dupixent | |
| 650 | 4 | |a Fasenra | |
| 650 | 4 | |a Inflation Reduction Act | |
| 650 | 4 | |a Medicare | |
| 650 | 4 | |a Nucala | |
| 650 | 4 | |a Part D | |
| 650 | 4 | |a Xolair | |
| 650 | 4 | |a benralizumab | |
| 650 | 4 | |a biologic | |
| 650 | 4 | |a chronic rhinosinusitis | |
| 650 | 4 | |a dupilumab | |
| 650 | 4 | |a mepolizumab | |
| 650 | 4 | |a nasal polyposis | |
| 650 | 4 | |a omalizumab | |
| 700 | 1 | |a Soler, Zachary M |e verfasserin |4 aut | |
| 700 | 1 | |a Schlosser, Rodney J |e verfasserin |4 aut | |
| 700 | 1 | |a Workman, Alan D |e verfasserin |4 aut | |
| 700 | 1 | |a Chapurin, Nikita |e verfasserin |4 aut | |
| 700 | 1 | |a Rowan, Nicholas R |e verfasserin |4 aut | |
| 700 | 1 | |a Dusetzina, Stacie B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International forum of allergy & rhinology |d 2011 |g (2024) vom: 11. März |w (DE-627)NLM209105178 |x 2042-6984 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:11 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/alr.23344 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 11 |c 03 | ||